Business / Finance

RSS

Lundbeck invests in Ossianix to focus on biotherapeutics for CNS disorders

Ossianix, Inc. today announced a strategic investment by H. Lundbeck A/S in the form of a Convertible Promissory Note. The proceeds from Lundbeck's investment is expected to allow Ossianix to generate biopharmaceuticals for the treatment of nervous system disorders by utilizing Ossianix's proprietary single domain antibody platform modeled on the shark vNAR structure.

3 Jan 2012

Anytime Fitness to open clubs in the Middle East

Anytime Fitness, the fastest-growing fitness club chain in the world, will soon open its first club in the Middle East. The first of several Anytime Fitness clubs in the State of Qatar opened on January 1, 2012.

2 Jan 2012

Lucid closes underwritten public offering

Lucid, Inc. today announced that it has closed its previously announced underwritten public offering of 1,388,000 units, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock.

31 Dec 2011

RBCC: 2012 could turn out to be better for the global biotechnology sector

With strong growth predicted for the biotech and pharmaceuticals industry in 2012, emerging biotech firm Rainbow Coral Corp. anticipates a prosperous new year ahead.

31 Dec 2011

China's revised Foreign Investment Catalogue 2011 moves healthcare service sectors to 'permitted' category

Concord Medical Services Holdings Limited, operator of the largest network of radiotherapy and diagnostic imaging centers in China, comments on the newly issued Foreign Investment Catalogue 2011 revision which moved healthcare service sectors to "permitted" from "restricted" category.

31 Dec 2011

Additional financing to fund Advaxis' cervical cancer trials

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has entered into a definitive Convertible Notes Purchase Agreement (Agreement) with certain accredited investors, for the purchase of the aggregate principal value of approximately $1.2 million of Convertible Promissory Notes (Notes) for an aggregate purchase price of approximately $1.0 million.

31 Dec 2011

Golden Meditech continues share repurchase program

Golden Meditech Holdings Limited, China's leading integrated healthcare enterprise, today announced that the Group has been repurchasing its shares from the market in the month of December 2011, accumulating a total of 58,104,000 shares in December 2011, equivalent to 2.84% of the Group's total outstanding shares as of today at a weighted average price of HK$0.84 per share.

31 Dec 2011

Chengdu Tianyin receives approval for renewed High Tech Enterprise status

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients today announced the approval of the Company's operating subsidiary, Chengdu Tianyin Pharmaceutical Co., Ltd's application for the renewal of its High Tech Enterprise Status in Chengdu, Sichuan Province of China.

30 Dec 2011

AMT raises € 2.5 million through private placement

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the Company has raised € 2.5 million in new equity by means of a private placement to three of its existing shareholders: Forbion Capital Partners, Gilde Healthcare Partners and Advent Venture Partners.

30 Dec 2011

Alexion to acquire 100% of capital stock of Enobia

Alexion Pharmaceuticals, Inc. and Enobia Pharma Corp. today announced that the companies have signed a definitive agreement under which Alexion will acquire 100% of the capital stock of Enobia.

29 Dec 2011

Delcath receives ISO 13485 Certification for Galway facility

Delcath Systems, Inc. today announced that the Company's Galway, Ireland location has achieved ISO 13485:2003 Certification—an internationally recognized quality standard designed to ensure that medical device manufacturers have the necessary comprehensive quality management systems in place to safely design, develop, manufacture and distribute medical devices in the European Union.

28 Dec 2011

Concord Medical provides update on Chang'an Hospital acquisition

Concord Medical Services Holdings Limited, operator of the largest network of radiotherapy and diagnostic imaging centers in China, today updated its progress on the pending acquisition of Chang'an Hospital.

28 Dec 2011

Nano3D's technology and revenues continue to impress RBCC

As Rainbow Coral Corp. continues its due diligence on Nano3D Biosciences (n3D), it's not just the early-stage biotech firm's groundbreaking technology that has impressed RBCC—It's also n3D's revenues.

28 Dec 2011

Weikang relocates to own headquarters building

Weikang Bio-Technology Group, Inc. Completes HQ Relocation After Purchasing Building For $14 Million And Answers Questions About Its Third Quarter Financials

28 Dec 2011

National Mentor Holdings fourth quarter revenue increases 5.0% to $271.5 million

National Mentor Holdings, Inc. today announced its financial results for the fourth quarter and fiscal year ended September 30, 2011.

27 Dec 2011

Hard Candy Fitness Moscow Center opens for workouts

Madonna in partnership with her manager Guy Oseary and Mark Mastrov, Chairman of New Evolution Ventures (NeV), announced their second Hard Candy Fitness Center in Moscow is now open for workouts.

26 Dec 2011

Wolters Kluwer sells pharma-related business to Springer Science+Business Media

Wolters Kluwer, a market-leading global information services company focused on professionals, today announced that it has completed the sale of its pharma-related Marketing & Publishing Services business to Springer Science+Business Media.

26 Dec 2011

CEL-SCI reports net loss of $26.8M for fiscal year ended September 30, 2011

CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2011.

26 Dec 2011

Acceleron Pharma raises $30 million through private financing

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced it raised a $30M private financing.

23 Dec 2011

Lexicon completes rights offering

Lexicon Pharmaceuticals, Inc. announced today that it has completed its previously announced rights offering pursuant to an effective shelf registration statement.

23 Dec 2011